The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant ...
Research led by Friedrich-Alexander-Universität Erlangen–Nürnberg provides evidence that teclistamab may offer therapeutic ...
ABS-CBN on MSN
Understanding ILD: The rare lung disease
Spotting ILDs may be challenging. Symptoms such as a dry cough, shortness of breath, and unexplained weight loss may go ...
The IMVARIA team conducted the pivotal VIRTUAL-BRONCH study of its new Bronchosolve solution to obtain data that underscores efficacy. In this study focused on better non-invasive diagnosis of lung ...
In her spare time, she found homes for unneeded lab animals in local kindergarten classrooms, complete with supplies, ...
AstraZeneca Plc and Daiichi Sankyo Co.’s cancer drug Enhertu bolstered outcomes for patients with early-stage breast cancer, ...
Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...
A real-world UK study shows that durvalumab following chemoradiotherapy effectively extends overall and progression-free ...
SystImmune & Bristol Myers Squibb announce first global phase I results of iza-bren, an EGFR x HER3 bispecific ADC, in patients with advanced solid tumours at ESMO 2025 ...
Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to ...
Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback